Artelo Biosciences shares soared more than 40% in pre-market trading after securing a fully-funded study for its synthetic cannabinoid. The agreement with Glaucoma UK and HSC R&D will evaluate ART27.13 for treating glaucoma. This news pushed retail sentiment on Stocktwits to "extremely bullish" territory with high volume.